ClinicalTrials.gg
CompletedNCT00868959Updated Apr 14, 2016Results posted

Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression

A Phase 3 interventional study of lurasidone in Bipolar Depression, sponsored by Sumitomo Pharma America, Inc.. Completed at 151 sites in 15 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-04-14.

Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
817
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing lurasidone in Bipolar Disorder — 2 open to participants now, 2 under way, none of them phase 3. lurasidone · Bipolar Disorder.

Enrollment
2nd of 17
817 · median 348
Started
2009
with 2 others
Phase 3
11 of 17
none open now
Registered
1st of 17
by date
Lead sponsor
8 of 17
Sumitomo Pharma America, Inc.

Among the 17 studies testing lurasidone in Bipolar Disorder, this one is the 2nd largest by enrollment, is one of 3 that started in 2009, is one of 11 in phase 3, and was the 1st registered.

Bipolar Disorder

1,685 studies on the registry are indexed under Bipolar Disorder; 267 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

2 of the 17 studies testing lurasidone in Bipolar Disorder are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About lurasidone

lurasidone: first FDA approval 2010 (LATUDA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 205 Bipolar Disorder studies recruiting now, 59 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 37 take children under 18; 50 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing lurasidone in Bipolar Disorder, or all of them as a file.
02

Study summary

This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe for the treatment of patients with bipolar I depression

03

Conditions studied

  • Bipolar Depression

Keywords

  • Bipolar
  • Depression
  • Lurasidone
  • Latuda
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is judged by the investigator to be suitable for participation in a 24-week clinical trial involving open-label lurasidone treatment
  • Subject has completed the 6-week treatment period and all required assessments on the final study visit (Day 42, Visit 8) of either Study D1050235, NCT#00868452 or Study D1050236, NCT#008668699.

Exclusion criteria

Exclusion Criteria:

  • Imminent risk of suicide, injury to self or to others, or damage to property
  • Subject has evidence of severe movement disorders.
  • Subject tests positive for drugs of abuse (at Visit 8 in Study D1050235, NCT#00868452 or D1050236, NCT#008688699).
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
817 participants (actual)

Study arms

  • Experimental
    lurasidone

    Drug: lurasidone

Interventions

  • Lurasidone 20-120 mg/d Flexibly Dosed - 24 weeks

06

What researchers measure

Primary outcomes

  1. Number of Participants With Serious and Non-serious Treatment-emergent Adverse Events Who Have Completed 24 Weeks of Extension Study Treatment

    Rate of treatment-emergent adverse events in subjects who have completed (ie, reached 6-week endpoint) of Study D1050235 (NCT00868452), Study D1050236 (NCT00868699) or Study D1050292 (NCT01284517)

    Time frame: 24 weeks

Secondary outcomes

  1. Change From Open-label Extension Baseline to Week 24 (Month 6/LOCF Endpoint) in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

    The MADRS is a clinician-rated assessment of the subject's level of depression. Ten items are rated on a Likert scale, from 0="Normal" to 6="Most Severe". The MADRS total score is calculated as the sum of ten items: reported sadness, apparent sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. The MADRS total score ranges from 0 to 60. Higher scores are associated with greater severity.

    Time frame: 24 weeks

  2. Change From Open-label Extension Baseline to Week 24 (Month 6/LOCF Endpoint) in Clinical Global Impressions Bipolar Version, Severity of Illness (CGI-BP-S) Score (Depression)

    This CGI-BP-S is a clinician-rated assessment of the subjects current severity of depression and ranges from 1="Normal, not ill" to 7="Very severly ill". Higher scores are associated with greater severity.

    Time frame: 24 weeks

07

Results

Posted Apr 1, 2014

Participant flow

Participant flow — Overall Study
MilestoneLurasidone
Started817
Completed559
Not completed258

Outcome measures

PrimaryNumber of Participants With Serious and Non-serious Treatment-emergent Adverse Events Who Have Completed 24 Weeks of Extension Study Treatment

Rate of treatment-emergent adverse events in subjects who have completed (ie, reached 6-week endpoint) of Study D1050235 (NCT00868452), Study D1050236 (NCT00868699) or Study D1050292 (NCT01284517)

Time frame:
24 weeks
Reported as:
Number · participants
Number of Participants With Serious and Non-serious Treatment-emergent Adverse Events Who Have Completed 24 Weeks of Extension Study Treatment
participantsLurasidone
Number of Participants With Serious and Non-serious Treatment-emergent Adverse Events Who Have Completed 24 Weeks of Extension Study Treatment529
SecondaryChange From Open-label Extension Baseline to Week 24 (Month 6/LOCF Endpoint) in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

The MADRS is a clinician-rated assessment of the subject's level of depression. Ten items are rated on a Likert scale, from 0="Normal" to 6="Most Severe". The MADRS total score is calculated as the sum of ten items: reported sadness, apparent sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. The MADRS total score ranges from 0 to 60. Higher scores are associated with greater severity.

Time frame:
24 weeks
Reported as:
Mean · units on a scale
Change From Open-label Extension Baseline to Week 24 (Month 6/LOCF Endpoint) in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
units on a scaleLurasidone
Change From Open-label Extension Baseline to Week 24 (Month 6/LOCF Endpoint) in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score-4.4 ± 10.60
SecondaryChange From Open-label Extension Baseline to Week 24 (Month 6/LOCF Endpoint) in Clinical Global Impressions Bipolar Version, Severity of Illness (CGI-BP-S) Score (Depression)

This CGI-BP-S is a clinician-rated assessment of the subjects current severity of depression and ranges from 1="Normal, not ill" to 7="Very severly ill". Higher scores are associated with greater severity.

Time frame:
24 weeks
Reported as:
Mean · units on a scale
Change From Open-label Extension Baseline to Week 24 (Month 6/LOCF Endpoint) in Clinical Global Impressions Bipolar Version, Severity of Illness (CGI-BP-S) Score (Depression)
units on a scaleLurasidone
Change From Open-label Extension Baseline to Week 24 (Month 6/LOCF Endpoint) in Clinical Global Impressions Bipolar Version, Severity of Illness (CGI-BP-S) Score (Depression)-0.58 ± 1.325

Adverse events

Collected over 24 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lurasidone—24/813 (3%)246/813 (30.3%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventLurasidone
DepressionPsychiatric disorders6/813
Depression SuicidalPsychiatric disorders2/813
ManiaPsychiatric disorders2/813
Suicide AttemptPsychiatric disorders2/813
PancreatitisGastrointestinal disorders1/813
Disease ProgressionGeneral disorders1/813
HypersensitivityImmune system disorders1/813
AppendicitisInfections and infestations1/813
Hand FractureInjury, poisoning and procedural complications1/813
Humerous FractureInjury, poisoning and procedural complications1/813
Most frequent other events
Most frequent other events
EventLurasidone
AkathisiaNervous system disorders66/813
HeadacheNervous system disorders63/813
NauseaGastrointestinal disorders62/813
InsomniaPsychiatric disorders52/813
AnxietyPsychiatric disorders47/813
ParkinsonismNervous system disorders43/813

Baseline characteristics

Safety population - received at least one dose of study medication

Age, Continuous
Age, Continuous(years)Lurasidone
Mean42.7 ± 12.03
Age, Categorical
Age, Categorical(Participants)Lurasidone
<=18 years6
Between 18 and 65 years790
>=65 years17
Sex: Female, Male
Sex: Female, Male(Participants)Lurasidone
Female427
Male386
Region of Enrollment
Region of Enrollment(participants)Lurasidone
United States283
Slovakia19
Ukraine78
Lithuania16
Russian Federation31
Colombia15
India128
France23
Czech Republic108
Canada14
Poland12
Romania9
Peru12
South Africa56
Japan6
Germany3
08

Study locations

151 sites
  • Woodland International Research Inc
    Little Rock, Arkansas 72211, United States
  • South Coast Clinical Trials Inc.
    Anaheim, California 92804, United States
  • Catalina Research Institute
    Chino, California 91710, United States
  • Clinical Innovations Inc.
    Costa Mesa, California 92626, United States
  • Synergy Escondido
    Escondido, California 92025, United States
  • Collaborative Neuroscience Network Inc
    Garden Grove, California 92645, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • Florida Clinical Research Center LLC
    Maitland, California 32751, United States
  • Excell Research, Inc
    Oceanside, California 92056, United States
  • University of California at Irvine Medical Center
    Orange, California 92868, United States
  • CNRI - Los Angeles LLC
    Pico Rivera, California 90660, United States
  • Clinical Innovations Inc.
    Riverside, California 92506, United States
  • California Neuropsychopharmacology Clinical Research Instit
    San Diego, California 92102, United States
  • Artemis Institute for Clinical Research LLC
    San Diego, California 92123, United States
  • Sharp Mesa Vista Hospital
    San Diego, California 92123, United States
  • Clinical Innovations Inc.
    Santa Ana, California 92705, United States
  • Stanford University School of Medicine
    Stanford, California 94305, United States
  • Collaborative Neuroscience Network Inc.
    Torrance, California 90502, United States
  • University of Colorado
    Aurora, Colorado 80045, United States
  • MCB Clinical Research Centers-Colorado Springs
    Colorado Springs, Colorado 80917, United States
  • Florida Clinical Research Center LLC
    Bradenton, Florida 34208, United States
  • Florida Clinical Research Center LLC
    Fruitland park, Florida 34731, United States
  • Accurate Clinical Trials
    Kissimmee, Florida 34741, United States
  • Clinical Neuroscience Solutions INc.
    Orlando, Florida 32806, United States
  • University of South Florida Institute - Tampa
    Tampa, Florida 33613, United States
  • Janus Center for Psychiatric Research
    West Palm Beach, Florida 33407, United States
  • Northwest Behavioral Research Center
    Rosewekk, Georgia 30076, United States
  • Institute for Behavioral Medicine LLC
    Smyrna, Georgia 30080, United States
  • American Medical Research
    Oak Brook, Illinois 60523, United States
  • Lake Charles Clinical Trials LLC
    Lake Charles, Louisiana 70601, United States
  • Booker, J. Gary, MD. APMC
    Shreveport, Louisiana 71104, United States
  • Sheppard Pratt Health System
    Baltimore, Maryland 21285, United States
  • Capitol Clinical Research
    Rockville, Maryland 20852, United States
  • Precise Research Centers
    Flowood, Mississippi 39232, United States
  • Midwest Research Group
    St. Charles, Missouri 63301, United States
  • CRI Worldwide, LLC
    Willingboro, New Jersey 08046, United States
  • Albuquerque Neuroscience Inc.
    Albuquerque, New Mexico 87109, United States
  • Social Psychiatry Research Institute
    Brooklyn, New York 11235, United States
  • Neurobehavioral Research, Inc
    Cedarhurst, New York, United States
  • Village Clinical Research Inc.
    New York, New York 10003, United States
  • Medical & Behavioral Health Research PC
    New York, New York 10023, United States
  • Finger Lakes Clinical Research
    Rochester, New York 14618, United States
  • Zarzar Psychiatric Associates PLLC
    Raleigh, North Carolina 27607, United States
  • Richard H. Weisler & Associates
    Raleigh, North Carolina 27609, United States
  • Quest Therapeutics
    Avon Lake, Ohio 44012, United States
  • Psychiatric Professional Services Inc
    Cincinnati, Ohio 45267, United States
  • Mood Disorders Program-UHCMC
    Cleveland, Ohio 44106, United States
  • MetroHealth System
    Cleveland, Ohio 44122, United States
  • Midwest Clinical Research Center
    Dayton, Ohio 45408, United States
  • Summit Research Network (Oregon) Inc.
    Portland, Oregon 97210, United States
  • Lehigh Valley Hospital
    Allentown, Pennsylvania 18103, United States
  • Clinical Neuroscience Solutions Inc.
    Memphis, Tennessee 38119, United States
  • FutureSearch Clinical Trials LP
    Austin, Texas 78756, United States
  • FutureSearch Trials
    Dallas, Texas 75231, United States
  • Pillar Clinical Research LLC
    Dallas, Texas 75243, United States
  • Red Oak Psychiatry Associates, PA
    Houston, Texas 77090, United States
  • Wharton Research Center
    Wharton, Texas 77488, United States
  • Summit Research Network (Seattle) LLC
    Seattle, Washington 98104, United States
  • Clinical Research Group Edmonton
    Edmonton, Alberta T6L 6W6, Canada
  • Okanagan Clinical Trials
    Kelowna, British Columbia V1Y 2H4, Canada
  • Pierre-Janet Hospital
    Gatineau, Quebec J9A 1K7, Canada
  • Hopital Louis-H Lafontaine
    Montreal, Quebec H1N 3M5, Canada
  • Centro de Investigaciones y Proyectos en Neurociencias CIPNA Investigations
    Barranquilla, Colombia
  • E.S.E. Hospital Mental de Antioquia
    Bello, Colombia
  • Centro de Investigacion y Atencion para la Salud Mental
    Bogota, Colombia
  • Centro de Investigaciones del Sistema Nerviosa Limitada-Gr
    Bogota, Colombia
  • Saint Anne, s.r.o., Psychiatricke oddeleni
    Brno - mesto, 602 00, Czech Republic
  • BIALBI s.r.o. Psychiatricke oddeleni
    Litomerice, 412 01, Czech Republic
  • Psychiatricka ambulance Prosek
    Lovosicka, Czech Republic
  • Vojenska nemocnice Olomouc
    Olomouc, 779 00, Czech Republic
  • Clintrial, s.r.o.
    Praha, 10 100 00, Czech Republic
  • Psychiatry Trial s.r.o.
    Praha, 158 00, Czech Republic
  • Medical Services Prague s.r.o.
    Praha, 6 160 00, Czech Republic
  • Hopital Caremeau, Service de Psychiatrie A
    Nimes Cedex, 30 30029, France
  • Zans Ritter, Marcel
    Orvault, 44700, France
  • S V Medical College
    Tirupati, Andh Prad 517507, India
  • Vijayawada Institute of Mental Health and Neurosciences, Psychiatry
    Vijaywada, Andh Prad 520002, India
  • Brain Mind Behaviour Neurosciences Research Institute
    Vishakhapatnam, Andh Prad 530002, India
  • Seth K M School of P G Medicine & Research
    Ahmedabad, Gujarat 380006, India
  • Mental Illness Treatment Rehabilitation Foundation (MITR)
    Ahmedabad, Gujarat 380013, India
  • Brij Psychiatry Hospital & Muskaan Research Centre
    Vadodara, Gujarat 390001, India
  • Spandana Nursing Home
    Bangalore, Karna 560010, India
  • Abhava Hospital
    Bangalore, Karna 560027, India
  • K.S. Hegde Medical Academy
    Mangalore, Karna 575018, India
  • Shanti Nursing Home
    Aurangabad, Mahara 431001, India
  • Poona Hospital & Research Center
    Pune, Mahara 411 030, India
  • Mahatma Gandhi Institute of Medical Sciences
    Wardha, Mahara 442001, India
  • Dr. Tambi's Neuropsychiatry Center
    Jaipur, Rajaasthan 302017, India
  • R.K. Yadav Memorial Mental Health & De-Addiction Hospital Psychiatry
    Jaipur, Rajasthan 302021, India
  • Mahendru Psychiatric Centre
    Kanpur, Uttar Prad 208005, India
  • Manobal Med. Research Centre
    Lucknow, Uttar Prad 226006, India
  • Cosmos Hospitals-Delhi Psychiatry Center-Dept. of Psychiatry
    Delhi, 110092, India
  • Shree Hatkesh Health Foundation
    Gujarat, 362002, India
  • Samvedna Hospitals
    Gujarat, 380006, India
  • Chhatrapati Shahuji Maharaj
    Lucknow, 22603, India
  • Sujata Dirla Hospital & Research Centre
    Mahara, 422101, India
  • Ongata Hospital
    Hachioji-shi, 192-0153, Japan
  • Kohnodai Hp., National Center for Global Health and Medicine
    Ichikawa-sha, 272-8516, Japan
  • NHO Hizen Psychiatric Center
    Kanzaki-gun, 842-0192, Japan
  • National Center of Neurology and Psychiatry
    Kodaira-shi, 187-8551, Japan

Showing the first 100 of 151 sites across 15 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Forester BP, Sajatovic M, Tsai J, Pikalov A, Cucchiaro J, Loebel A. Safety and Effectiveness of Long-Term Treatment with Lurasidone in Older Adults with Bipolar Depression: Post-Hoc Analysis of a 6-Month, Open-Label Study. Am J Geriatr Psychiatry. 2018 Feb;26(2):150-159. doi: 10.1016/j.jagp.2017.08.013. Epub 2017 Oct 10. PubMed 29146409 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2009, a primary completion of Feb 2013 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2014, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2009
First posted
Mar 25, 2009
Start
Apr 2009
Primary completionActual
Feb 2013
CompletionActual
Feb 2013
Results first posted
Apr 1, 2014
Last update
Apr 14, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00868959
Responsible party
Sponsor
First posted
Mar 25, 2009
Start date
Apr 2009
Primary completion
Feb 2013
Completion
Feb 2013
Results posted
Apr 1, 2014
Last update
Apr 14, 2016

Study contacts

Medical Director, MD
study director · Sumitomo Pharma America, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lurasidone

Start the discussion